Dr. James O. Armitage is currently the Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center. He is board certified in internal medicine, medical oncology, and hematology, and a Fellow of both the American and Royal College of Physicians and of the American Association for the Advancement of Sciences. He has served on many national/international oncology committees, including the United States National Cancer Advisory Board and the French National Cancer Advisory Board. He is past president of both ASCO and the American Society of Blood and Marrow Transplantation and has served on multiple international committees. He has numerous honors, including the Claude Jacquillat Award for achievement in Clinical Oncology, the San Salvatore Foundation Research Award, and the Richard and Hinda Rosenthal Foundation Award from the American Association of Cancer Research. Dr. Armitage has published more than 562 papers and written 110 chapters, and is co-editor of 27 books.
The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of NCCN.
William C. Wood, MD, is Distinguished Joseph Brown Whitehead Professor of Surgery at Emory University School of Medicine and Professor of Global Health in the Hubert Department of Global Health in the Rollins School of Public Health. Since 2012 he has served as Academic Dean of PAACS' ten surgical residency programs in Africa. He has devoted his research efforts to oncology, first in the immunology of autoantibodies to tumor associated antigens, then in clinical trials of multimodality treatment of breast cancer. He is a Senior Research Fellow of the International Prevention Research Institute of Lyon, France, and serves on the Board of Advisors of the Africa Oxford Cancer Foundation, Oxford. He has served as Chair of the Cancer and Leukemia Group B Breast Committee, Chair of the Eastern Cooperative Oncology Group Breast Committee, Chair of the NCI Breast Intergroup, Co-Chair of the Early Breast Cancer Trialists' Collaborative Group (Oxford), Co-Chair of the NCI Breast Cancer Steering Committee, and Co-Chair of BIG-NABCG. He has been a Governor of the American College of Surgeons, a Director of ASCO, a member of the Board of Scientific Advisors of NCI, and President of the Society of Surgical Oncology, the Southeastern Surgical Congress, the Georgia Surgical Association, the Atlanta Surgical Association, and the Southern Surgical Association. He is Editor-in-Chief of Oncology, Associate Editor of Annals of Surgical Oncology, and has written over 280 full-length scientific articles, over 35 book chapters, and has edited or co-edited 7 books, including the 3-volume Oxford Textbook of Surgery, 2nd Ed.
Dr. Dan L. Longo is Professor of Medicine at Harvard Medical School in the Division of Hematology at Brigham and Women's Hospital and Deputy Editor of the New England Journal of Medicine. He is a Master of the American College of Physicians, a member of the American Society of Clinical Investigation and the Association of American Physicians, and a fellow of the American Association for the Advancement of Science. He has been active in research on the treatment of malignant lymphoma, including new treatments targeting CD30, CD40, HLA Class II molecules, and immunoglobulin idiotype. His laboratory work has focused in part on the regulation of lymphocyte proliferation, natural killer cell effects on hematopoiesis, and tumor-induced immunosuppression. He has published over 900 peer-reviewed papers, review articles, editorials, and book chapters and has been an editor of Harrison's Principles of Internal Medicine since 1994, including serving as Editor-in-Chief of the 18th edition. He has written or edited 25 books.
RaemaekersJM, AndreMP, FedericoM. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol2014;32:1188–1194.
RaemaekersJMAndreMPFedericoM. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol2014;32:1188–1194.
De LabartheA, RousselotP, Huguet-RigalF. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood2007;109:1408–1413.
De LabartheARousselotPHuguet-RigalF. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood2007;109:1408–1413.